These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18090396)

  • 1. Survival following HIV infection of a cohort followed up from seroconversion in the UK.
    Ewings FM; Bhaskaran K; McLean K; Hawkins D; Fisher M; Fidler S; Gilson R; Nock D; Brettle R; Johnson M; Phillips A; Porter K;
    AIDS; 2008 Jan; 22(1):89-95. PubMed ID: 18090396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.
    CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration
    HIV Med; 2000 Oct; 1(4):224-31. PubMed ID: 11737353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.
    Pérez-Hoyos S; del Amo J; Muga R; del Romero J; García de Olalla P; Guerrero R; Hernàndez-Aguado I;
    AIDS; 2003 Feb; 17(3):353-9. PubMed ID: 12556689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
    Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
    AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999.
    del Amo J; del Romero J; Barrasa A; Pérez-Hoyos S; Rodríguez C; Díez M; García S; Soriano V; Castilla J;
    Sex Transm Infect; 2002 Aug; 78(4):255-60. PubMed ID: 12181462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the risk of death after HIV seroconversion compared with mortality in the general population.
    Bhaskaran K; Hamouda O; Sannes M; Boufassa F; Johnson AM; Lambert PC; Porter K;
    JAMA; 2008 Jul; 300(1):51-9. PubMed ID: 18594040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.
    Detels R; Muñoz A; McFarlane G; Kingsley LA; Margolick JB; Giorgi J; Schrager LK; Phair JP
    JAMA; 1998 Nov; 280(17):1497-503. PubMed ID: 9809730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.
    Muga R; Ferreros I; Langohr K; de Olalla PG; Del Romero J; Quintana M; Alastrue I; Belda J; Tor J; Pérez-Hoyos S; Del Amo J;
    AIDS; 2007 Nov; 21(18):2521-7. PubMed ID: 18025889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
    García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
    J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
    Bhaskaran K; Mussini C; Antinori A; Walker AS; Dorrucci M; Sabin C; Phillips A; Porter K;
    Ann Neurol; 2008 Feb; 63(2):213-21. PubMed ID: 17894380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS).
    Dorrucci M; Balducci M; Pezzotti P; Sinicco A; Alberici F; Rezza G
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):65-70. PubMed ID: 10534148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.
    Mbizvo MT; Machekano R; McFarland W; Ray S; Bassett M; Latif A; Katzenstein D
    AIDS; 1996 Jul; 10(8):895-901. PubMed ID: 8828747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1998 Apr; 12(6):659-67. PubMed ID: 9583607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort.
    Altmann M; An der Heiden M; Scheufele R; Hartmann K; Houareau C; Bartmeyer B; Hamouda O;
    BMC Infect Dis; 2012 Apr; 12():94. PubMed ID: 22515400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda.
    Lutalo T; Gray RH; Wawer M; Sewankambo N; Serwadda D; Laeyendecker O; Kiwanuka N; Nalugoda F; Kigozi G; Ndyanabo A; Bwanika JB; Reynolds SJ; Quinn T; Opendi P
    AIDS; 2007 Nov; 21 Suppl 6():S15-9. PubMed ID: 18032934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users.
    Egea JM; Muga R; Sirera G; Clotet B; Tor J; Ardèvol M; Rey-Joly C; Muñoz A
    Epidemiol Infect; 2002 Oct; 129(2):325-33. PubMed ID: 12403108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.